Immediate targets 61, 59, 56, 53. Invalidation at 79. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically...
Healthy pipeline. Sitting at 3.32% yield and 8.62 P/E (norm is 18.65 and 5Y norm is 11.17) with earnings growth rate approx. 6.18% since 2000 but has increased to 15-16% if you look at the 10Y and 5Y norms. Estimates are for about 4-6% the next 2 years. A+ Credit Rating 48LT Debt to Cap PT $96 by 2023 using a 7% earnings growth rate and 12 P/E HUGE saucer...
Immediate targets 61,59, 56, 53. Invalidation at 79. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely...
BMY is presently in a wedge. Though a breakdown is certainly possible over the next decade, what are reasonable breakout levels to watch? This chart with Fib levels induced by the move from all-time lows to all-time highs gives some clues. Approximately $75 is first up, then approximately $120.
An upward breakout of the long-term resistance level could lead to an increase in the area of 81. In the long-term, the growth could continue to the area of 93.
Conviction: 4/5 might be better to buy when the stock goes over 1998 resistance General Thesis bouncing off of multi-cycle support (since 1974) Weekly RSI showing sliiight bullish divergence Growth Margins quite low compared to own history low growth Value very cheap Fundamentals low debt/asset ratio and plenty of cash to deal with...
Pays a dividend. This has a lot of different bullish patterns and if it falls through the floor, I'll laugh histaricly. Cup n' handle, bull-flaf, IHS. I'll leave a channel but feel free to find waldo! Cheers.
BMY: Bristol-Myers Squibb Company 2021-12-13 06:59:00 Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
Bristol-Myers Squibb Co. discovers, develops, licenses, manufactures and markets biopharmaceuticals worldwide. It offers products in hematology, oncology, cardiovascular and immunology therapeutic classes. It has agreements with Pfizer and Otsuka Pharmaceutical Co., Ltd. Revenue TTM 44.3B EBITDA TTM 18.8B EBITDA margin TTM 42.4% P/S 2.94 P/S 2.94 Dividend yield 3.2%
Watch out! Possible break out - leads to a stronger recovery rallye. oversold condition.
bmy buy.. cup and handle .. buy at 60.81 and stoploss at 59.23.. finally target is 73.60
Bullish cross of my EMAs. Stop at 58.08 Notes : The daily is so close and may act as resistance.
risk reward tool gives you idea about ENTRY ,STOP LOSS AND TARGET yes its good time to invest when I get the idea that this script is not bullish anymore I will let you know guy
www.tradingview.com Amazing RSI divergence on daily chart on a support key level. Waiting confirmation with volume or candelstick to setup the perfect entry time. Fibo 0.5 or 0.618 to be use for the TP as target. To keep on watchlist.
Bristol-Myers Squibb Company (BMY) oversold on the daily! Based on support and resistance we have: Price target: 67.50usd Stop loss: 55.90usd
Looks like a little more downside is possible through remainder of month, but BMY is primed for a very strong October if the algorithms are correct and history continues to be accurate. Based on historical movement, the trough could occur anywhere in the larger red box. The final targets are in the green boxes. The pending top should occur within the larger green...